BENCHMARK研究:经导管主动脉瓣植入术的简化临床路径
BENCHMARK研究在7个欧洲国家28个中心评估实施最佳实践对TAVI效率和安全性的影响,纳入严重症状性主动脉瓣狭窄患者,比较实施前后。
要点
- 实施BENCHMARK最佳实践可缩短TAVI患者住院和重症监护时间。
- 局部麻醉使用率提高,手术和介入时间缩短。
核心结论
- 广泛实施BENCHMARK最佳实践可提高TAVI路径效率,缩短住院时间并降低成本,而不影响患者安全。
研究设计与样本
- 研究纳入7个欧洲国家28个中心的严重症状性主动脉瓣狭窄患者,使用球囊扩张瓣膜行TAVI,比较实施BENCHMARK最佳实践前后。
- 2020年1月至2023年3月,实施前记录897例患者,实施后记录1491例患者。
主要发现
- 平均住院时间从7.7±7.0天降至5.8±5.6天(中位数6 vs 4天;P < .001)。
- 重症监护时间从1.8天降至1.3天(中位数1.1 vs 0.9天;P < .001)。
- 局部麻醉使用率从84.3%增至96.1%(P < .001),手术时间中位数从60分钟降至47分钟(P < .001),介入时间从95分钟降至85分钟(P < .001)。
临床怎么用
- 临床可借鉴BENCHMARK最佳实践优化TAVI围术期流程,如增加局部麻醉使用、缩短手术时间,以缩短住院和重症监护时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. METHODS: This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety. RESULTS: Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%). CONCLUSIONS: Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.
引用
- Frank D, Durand E, Lauck S, et al. A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study. Eur Heart J. 2024. PMID: 38554125. doi:10.1093/eurheartj/ehae147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。